© 2001 by European Society of Cardiology
Copyright © 2001, European Society of Cardiology
Cardiac remodeling after long term norepinephrine treatment in rats
aCarl-Ludwig-Institute of Physiology, University of Leipzig, Liebigstr. 27, D-04103 Leipzig, Germany
bGerhard-Domagk-Institute of Pathology, University of Münster, Münster, Germany
* Tel.: +49-0341-971-5500; fax: +49-0341-971-5509 barw{at}medizin.uni-leipzig.de
Objective: In this study we have tested the hypothesis that degradation of collagen by matrix metalloproteinase 2 (MMP-2) precedes the deposition of extracellular matrix (ECM) after long term norepinephrine (NE) treatment. Methods: Female Sprague–Dawley rats received continuous i.v. infusion of NE (0.1 mg/kg·h) for 1, 2, 3, 4 and 14 days. Heart function and weight as well as expression of cardiac colligin and of collagen I and III were examined. Furthermore, we have assessed the degradation pathway of collagen by measuring the mRNA and activity of myocardial MMP-2 and tissue inhibitor of metalloproteinase 2 (TIMP-2) as well as the protein level of TIMP-2. Results: NE induced hypertrophy predominantly of the left ventricle (LV) in a time-dependent manner. It increased the mRNAs of colligin, collagen I and III, and of MMP-2 and TIMP-2 as well as MMP-2 activity in two phases: In the initial phase, at 3 and 4 days, the mRNA of colligin and of collagen I and III was elevated predominantly in the LV, MMP-2 and TIMP-2 mRNA, as well as TIMP-2 protein and MMP-activity were increased in both ventricles. The second phase, after 14 days, was characterized by a less pronounced increase in colligin, collagen I and III and in MMP-2 activity which occurred exclusively in the LV. Finally, long-term treatment with NE induced a 37% increase in interstitial fibrosis which was shown to occur exclusively in the LV after 14 days. Conclusion: NE treatment induced fibrosis exclusively in the LV which was associated with hypertrophy predominantly of the LV. The elevated MMP-2 activity seems to be necessary for the ECM to adapt to the enlargement of myocytes and to reduce overproduction of collagen.
KEYWORDS Adrenergic (ant)agonists; Extracellular matrix; Fibrosis; Gene expression; Hemodynamics; Hypertrophy; Receptors
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
S. Klotz, D. Burkhoff, I. M. Garrelds, F. Boomsma, and A.H.J. Danser The impact of left ventricular assist device-induced left ventricular unloading on the myocardial renin-angiotensin-aldosterone system: therapeutic consequences? Eur. Heart J., April 1, 2009; 30(7): 805 - 812. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. R. Mobine, A. B. Baker, L. Wang, H. Wakimoto, K. C. Jacobsen, C. E. Seidman, J.G. Seidman, and E. R. Edelman Pheochromocytoma-Induced Cardiomyopathy is Modulated by the Synergistic Effects of Cell-Secreted Factors Circ Heart Fail, March 1, 2009; 2(2): 121 - 128. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Husse, W. Briest, L. Homagk, G. Isenberg, and M. Gekle Cyclical mechanical stretch modulates expression of collagen I and collagen III by PKC and tyrosine kinase in cardiac fibroblasts Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2007; 293(5): R1898 - R1907. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M. Deschamps and F. G. Spinale Pathways of matrix metalloproteinase induction in heart failure: Bioactive molecules and transcriptional regulation Cardiovasc Res, February 15, 2006; 69(3): 666 - 676. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Spallarossa, P. Altieri, S. Garibaldi, G. Ghigliotti, C. Barisione, V. Manca, P. Fabbi, A. Ballestrero, C. Brunelli, and A. Barsotti Matrix metalloproteinase-2 and -9 are induced differently by doxorubicin in H9c2 cells: The role of MAP kinases and NAD(P)H oxidase Cardiovasc Res, February 15, 2006; 69(3): 736 - 745. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. H. Hohnloser Ventricular Arrhythmias: Antiadrenergic Therapy for the Patient with Coronary Artery Disease Journal of Cardiovascular Pharmacology and Therapeutics, October 1, 2005; 10(4_suppl): S23 - S31. [Abstract] [PDF] |
||||
![]() |
H. Kiriazis, X.-J. Du, X. Feng, E. Hotchkin, T. Marshall, S. Finch, X.-M. Gao, G. Lambert, J. K. Choate, and D. M. Kaye Preserved left ventricular structure and function in mice with cardiac sympathetic hyperinnervation Am J Physiol Heart Circ Physiol, October 1, 2005; 289(4): H1359 - H1365. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Banfi, V. Cavalca, F. Veglia, M. Brioschi, S. Barcella, L. Mussoni, L. Boccotti, E. Tremoli, P. Biglioli, and P. Agostoni Neurohormonal activation is associated with increased levels of plasma matrix metalloproteinase-2 in human heart failure Eur. Heart J., March 1, 2005; 26(5): 481 - 488. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Briest, L. Homagk, B. Rassler, B. Ziegelhoffer-Mihalovicova, H. Meier, A. Tannapfel, S. Leiblein, A. Saalbach, A. Deten, and H.-G. Zimmer Norepinephrine-Induced Changes in Cardiac Transforming Growth Factor-{beta} Isoform Expression Pattern of Female and Male Rats Hypertension, October 1, 2004; 44(4): 410 - 418. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Kuramochi, C. C. Lim, X. Guo, W. S. Colucci, R. Liao, and D. B. Sawyer Myocyte contractile activity modulates norepinephrine cytotoxicity and survival effects of neuregulin-1{beta} Am J Physiol Cell Physiol, February 1, 2004; 286(2): C222 - C229. [Abstract] [Full Text] |
||||
![]() |
A. Deten, H. Millar, and H.-G. Zimmer Catheterization of pulmonary artery in rats with an ultraminiature catheter pressure transducer Am J Physiol Heart Circ Physiol, November 1, 2003; 285(5): H2212 - H2217. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Briest, A. Holzl, B. Rassler, A. Deten, H. A Baba, and H.-G. Zimmer Significance of matrix metalloproteinases in norepinephrine-induced remodelling of rat hearts Cardiovasc Res, February 1, 2003; 57(2): 379 - 387. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Portik-Dobos, M. P. Anstadt, J. Hutchinson, M. Bannan, and A. Ergul Evidence for a Matrix Metalloproteinase Induction/Activation System in Arterial Vasculature and Decreased Synthesis and Activity in Diabetes Diabetes, October 1, 2002; 51(10): 3063 - 3068. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Briest Do we have a new early marker of chronic transplant dysfunction now? Cardiovasc Res, June 1, 2002; 54(3): 492 - 494. [Full Text] [PDF] |
||||








